Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex
暂无分享,去创建一个
Frank Baas | Eleonora Aronica | Sebastiano Cavallaro | F. Baas | E. Aronica | S. Cavallaro | A. Iyer | Anand Iyer | Anneloor L.M.A. ten Asbroek | Giovanna Morello | A. T. Asbroek | Giovanna Morello
[1] C. Armon. Environmental Risk Factors for Amyotrophic Lateral Sclerosis , 2001, Neuroepidemiology.
[2] J. Huot,et al. Ephrin signaling in axon guidance , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[3] J. Julien,et al. Cycling at the interface between neurodevelopment and neurodegeneration , 2002, Cell Death and Differentiation.
[4] Asako Koike,et al. A mutation database for amyotrophic lateral sclerosis , 2010, Human mutation.
[5] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[6] J. Connor,et al. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[7] Karunya K. Kandimalla,et al. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice , 2005, Brain Research.
[8] Ammar Al-Chalabi,et al. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? , 2011, Nature Reviews Neurology.
[9] Han-Jou Chen,et al. Characterization of the Properties of a Novel Mutation in VAPB in Familial Amyotrophic Lateral Sclerosis , 2010, The Journal of Biological Chemistry.
[10] D. Price,et al. Amyotrophc Lateral Sclerosis: Alterations in Neurotransmitter Receptors , 2004 .
[11] Q. Zhu,et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Ludolph,et al. Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.
[13] M. Dubois‐Dauphin,et al. Bax and Bcl‐2 Interaction in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.
[14] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[15] M. Yamauchi,et al. Decreased type IV collagen of skin and serum in patients with amyotrophic lateral sclerosis , 1998, Neurology.
[16] A. Ferguson,et al. Adiponectin modulates excitability of rat paraventricular nucleus neurons by differential modulation of potassium currents. , 2010, Endocrinology.
[17] B. Crain,et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. , 1998, American journal of human genetics.
[18] S. Sasaki. Autophagy in Spinal Cord Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis , 2011, Journal of neuropathology and experimental neurology.
[19] Rüdiger Klein,et al. Eph/ephrin signaling in morphogenesis, neural development and plasticity. , 2004, Current opinion in cell biology.
[20] Alexander R. Abbas,et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data , 2005, Genes and Immunity.
[21] Martina Wiedau-Pazos,et al. Integrative gene-tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis. , 2010, Human molecular genetics.
[22] D. Michel,et al. [Fatal peripheral neuropathy with predominant motor involvement associated with anti-MAG IgM monoclonal gammapathy]. , 1993, Revue neurologique.
[23] E. Melamed,et al. Spinal Cord mRNA Profile in Patients with ALS: Comparison with Transgenic Mice Expressing the Human SOD-1 Mutant , 2009, Journal of Molecular Neuroscience.
[24] M. Tohyama,et al. Familiar amyotrophic lateral sclerosis (FALS)-linked SOD1 mutation accelerates neuronal cell death by activating cleavage of caspase-4 under ER stress in an in vitro model of FALS , 2010, Neurochemistry International.
[25] A. Al-Chalabi,et al. Keeping up with genetic discoveries in amyotrophic lateral sclerosis: The ALSoD and ALSGene databases , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[26] B. Pettmann,et al. Programmed Cell Death of Embryonic Motoneurons Triggered through the FAS Death Receptor , 1999, The Journal of cell biology.
[27] S. Ennis,et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis , 2006, Nature Genetics.
[28] Hiroshi Nishimune,et al. Motoneuron Death Triggered by a Specific Pathway Downstream of Fas Potentiation by ALS-Linked SOD1 Mutations , 2002, Neuron.
[29] E. Feldman,et al. Vascular endothelial growth factor prevents G93A‐SOD1‐induced motor neuron degeneration , 2009, Developmental neurobiology.
[30] Robert H. Brown,et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. , 2009, American journal of human genetics.
[31] G. Bernardi,et al. Molecular and synaptic changes in the hippocampus underlying superior spatial abilities in pre-symptomatic G93A+/+ mice overexpressing the human Cu/Zn superoxide dismutase (Gly93 → ALA) mutation , 2006, Experimental Neurology.
[32] Xun Hu,et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis , 2008, Science.
[33] Sean Ekins,et al. A novel method for generation of signature networks as biomarkers from complex high throughput data. , 2005, Toxicology letters.
[34] G. Bernardi,et al. Postsynaptic alteration of NR2A subunit and defective autophosphorylation of alphaCaMKII at threonine-286 contribute to abnormal plasticity and morphology of upper motor neurons in presymptomatic SOD1G93A mice, a murine model for amyotrophic lateral sclerosis. , 2011, Cerebral cortex.
[35] S. Petri,et al. Distribution of GABAA Receptor mRNA in the Motor Cortex of ALS Patients , 2003, Journal of neuropathology and experimental neurology.
[36] G. Stephanopoulos,et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. , 2004, Physiological genomics.
[37] Yuxin Fan,et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell–matrix adhesion biology , 2009, Human molecular genetics.
[38] J. Loeb,et al. Differential distribution of neuregulin in human brain and spinal fluid , 2009, Brain Research.
[39] R. Deane,et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration , 2008, Nature Neuroscience.
[40] M. Swash,et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[41] R. Tapia,et al. Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo , 2012, ASN neuro.
[42] J. H. Boo,et al. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? , 2009, Advanced drug delivery reviews.
[43] B. McConkey,et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis , 2008, Nature Genetics.
[44] L. Tessarollo,et al. Deletion of the BDNF Truncated Receptor TrkB.T1 Delays Disease Onset in a Mouse Model of Amyotrophic Lateral Sclerosis , 2012, PloS one.
[45] Olubunmi Abel,et al. ALSoD: A user‐friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics , 2012, Human mutation.
[46] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[47] J. Loeb,et al. Aberrant Neuregulin 1 Signaling in Amyotrophic Lateral Sclerosis , 2012, Journal of neuropathology and experimental neurology.
[48] I. Kruman. Why do Neurons Enter the Cell Cycle? , 2004, Cell cycle.
[49] J. Lowe,et al. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. , 1998, Neuropathology and applied neurobiology.
[50] D. Belsham,et al. Adipokine Gene Expression in a Novel Hypothalamic Neuronal Cell Line: Resistin-Dependent Regulation of Fasting-Induced Adipose Factor and SOCS-3 , 2007, Neuroendocrinology.
[51] A. Spalloni,et al. Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis. , 2013, Biochimica et biophysica acta.
[52] M. Michalopoulou,et al. Interleukin‐17 and interleukin‐23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? , 2010, Acta neurologica Scandinavica.
[53] N. Harel,et al. Reticulon-4A (Nogo-A) Redistributes Protein Disulfide Isomerase to Protect Mice from SOD1-Dependent Amyotrophic Lateral Sclerosis , 2009, The Journal of Neuroscience.
[54] G. Sobue,et al. Gene Expressions Specifically Detected in Motor Neurons (Dynactin 1, Early Growth Response 3, Acetyl-CoA Transporter, Death Receptor 5, and Cyclin C) Differentially Correlate to Pathologic Markers in Sporadic Amyotrophic Lateral Sclerosis , 2007, Journal of neuropathology and experimental neurology.
[55] Sebastiano Cavallaro,et al. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis , 2007, BMC Genomics.
[56] Robert H. Brown,et al. Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis , 1993, Journal of neurochemistry.
[57] J. Morris,et al. TDP‐43 A315T mutation in familial motor neuron disease , 2008, Annals of neurology.
[58] M. Fernando,et al. Expression of Vascular Endothelial Growth Factor and Its Receptors in the Central Nervous System in Amyotrophic Lateral Sclerosis , 2006, Journal of neuropathology and experimental neurology.
[59] S. Hadano,et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2 , 2001, Nature Genetics.
[60] Yasushi Hiraoka,et al. Mutations in Dynein Link Motor Neuron Degeneration to Defects in Retrograde Transport , 2003, Science.
[61] E. Stefani,et al. Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel α1 subunit , 1994 .
[62] M. Cozzolino,et al. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis1 , 2009, The Journal of Immunology.
[63] Margaret A. Johnson,et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death , 1999, Annals of neurology.
[64] D. Leppert,et al. Matrix metalloproteinases in neuromuscular disease , 2007, Muscle & nerve.
[65] M. Mattson,et al. Adiponectin protects rat hippocampal neurons against excitotoxicity , 2011, AGE.
[66] D. C. Carter,et al. Atomic structure and chemistry of human serum albumin , 1993, Nature.
[67] M. Mattson,et al. DNA damage responses in neural cells: Focus on the telomere , 2007, Neuroscience.
[68] R. Bowser,et al. DECREASED mRNA EXPRESSION OF TIGHT JUNCTION PROTEINS IN LUMBAR SPINAL CORDS OF PATIENTS WITH ALS , 2009, Neurology.
[69] P. Carmeliet,et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.
[70] L. Defebvre,et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? , 2005, Neurology.
[71] J. Wands,et al. P53- and CD95-associated apoptosis in neurodegenerative diseases. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[72] Y. Itoyama,et al. Intrathecal Delivery of Hepatocyte Growth Factor From Amyotrophic Lateral Sclerosis Onset Suppresses Disease Progression in Rat Amyotrophic Lateral Sclerosis Model , 2007, Journal of neuropathology and experimental neurology.
[73] M. Beal,et al. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice , 2006, Journal of the Neurological Sciences.
[74] W. Robberecht,et al. Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis , 2005, Neuroreport.
[75] Claire L. Simpson,et al. Amyotrophic lateral sclerosis as a complex genetic disease. , 2006, Biochimica et biophysica acta.
[76] P. Demetter,et al. Impaired blood–brain and blood–spinal cord barriers in mutant SOD1-linked ALS rat , 2009, Brain Research.
[77] A. Malaspina,et al. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays , 2001, Journal of neurochemistry.
[78] Toshikazu Nakamura,et al. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS , 2007, Neuroscience Research.
[79] I. Niebroj-Dobosz,et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2010, European journal of neurology.
[80] R. Clatterbuck,et al. Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo , 1993, Neuron.
[81] K. Abe,et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis , 2011, Journal of neuroscience research.
[82] S. Imran,et al. Adipokine Gene Expression in Brain and Pituitary Gland , 2007, Neuroendocrinology.
[83] C. Cheroni,et al. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: Implication for protein aggregation and immune response , 2012, Progress in Neurobiology.
[84] M. Strong,et al. Innate immunity in amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.
[85] G. Bernardi,et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis , 2010, Brain : a journal of neurology.
[86] P. Spano,et al. Leptin Is Induced in the Ischemic Cerebral Cortex and Exerts Neuroprotection Through NF-&kgr;B/c-Rel–Dependent Transcription , 2009, Stroke.
[87] D. Cleveland,et al. Slowing of axonal transport is a very early event in the toxicity of ALS–linked SOD1 mutants to motor neurons , 1999 .
[88] Xun Hu,et al. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 , 2009, Science.
[89] Shin J. Oh,et al. Mutant dynactin in motor neuron disease , 2003, Nature Genetics.
[90] K. Herrup,et al. Divide and Die: Cell Cycle Events as Triggers of Nerve Cell Death , 2004, The Journal of Neuroscience.
[91] S. Niclou,et al. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease , 2006, Molecular and Cellular Neuroscience.
[92] E. Shohami,et al. Neurodegeneration Induces Upregulation of Beclin 1 , 2006, Autophagy.
[93] G. Coppola,et al. Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases , 1991, The Italian Journal of Neurological Sciences.
[94] E. Beghi,et al. The epidemiology of ALS and the role of population-based registries. , 2006, Biochimica et biophysica acta.
[95] Ichiro Kanazawa,et al. Glutamate receptors: RNA editing and death of motor neurons , 2004, Nature.
[96] P. V. van Rijen,et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy , 2005, Neuropathology and applied neurobiology.
[97] E. Stefani,et al. Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. , 1994, Annals of neurology.
[98] M. Tsumura,et al. Decreased plasma levels of fibronectin in amyotrophic lateral sclerosis , 2000, Acta neurologica Scandinavica.
[99] Woong Sun,et al. Overexpression of HGF Retards Disease Progression and Prolongs Life Span in a Transgenic Mouse Model of ALS , 2002, The Journal of Neuroscience.
[100] P. Liesi,et al. Selective overexpression of γ1 laminin in astrocytes in amyotrophic lateral sclerosis indicates an involvement in ALS pathology , 2007, Journal of neuroscience research.
[101] T. Gillingwater,et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. , 2004, American journal of human genetics.
[102] Paul G. Ince,et al. Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS) , 2010, PloS one.
[103] I. Vincent,et al. The cell cycle and human neurodegenerative disease. , 2003, Progress in cell cycle research.
[104] S. Lorenzl,et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.
[105] E. Aronica,et al. Immunohistochemical localization of vascular endothelial growth factor receptors‐1, ‐2 and ‐3 in human spinal cord: altered expression in amyotrophic lateral sclerosis , 2004, Neuropathology and applied neurobiology.
[106] J L Haines,et al. Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .
[107] B. Tang,et al. Nogo-A and Nogo-66 receptor in amyotrophic lateral sclerosis , 2008, Journal of cellular and molecular medicine.
[108] L. Greene,et al. Cell cycle molecules and vertebrate neuron death: E2F at the hub , 2004, Cell Death and Differentiation.
[109] Esther B. E. Becker,et al. Cell cycle regulation of neuronal apoptosis in development and disease , 2004, Progress in Neurobiology.
[110] M. Gurney,et al. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .
[111] D. Maraganore,et al. Beyond Parkinson Disease: Amyotrophic Lateral Sclerosis and the Axon Guidance Pathway , 2008, PloS one.
[112] J. Seeburger,et al. Experimental Rationale for the Therapeutic Use of Neurotrophins in Amyotrophic Lateral Sclerosis , 1993, Experimental Neurology.
[113] R. Pasterkamp,et al. Axon guidance proteins: Novel therapeutic targets for ALS? , 2009, Progress in Neurobiology.
[114] A. Kakita,et al. Neuropathology with Clinical Correlations of Sporadic Amyotrophic Lateral Sclerosis: 102 Autopsy Cases Examined Between 1962 and 2000 , 2003, Brain pathology.
[115] L. Defebvre,et al. Elevated IL-6 and TNF-α levels in patients with ALS: Inflammation or hypoxia? , 2005, Neurology.
[116] R. Vos,et al. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis , 2003, The Lancet.
[117] Q. Zhu,et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[118] I. Joo,et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice , 2009, Gene Therapy.
[119] Dong-Hoon Shin,et al. Immunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1G93A mutant transgenic mice , 2003, Brain Research.
[120] B. Fadeel,et al. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS , 2004, Annals of neurology.
[121] Bo Yang,et al. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model , 2011, Glia.
[122] K. Herrup,et al. Cell division in the CNS: protective response or lethal event in post-mitotic neurons? , 2007, Biochimica et biophysica acta.
[123] R. Nitsch,et al. Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis , 2000, Neurology.
[124] J. Julien,et al. A neurotoxic peripherin splice variant in a mouse model of ALS , 2003, The Journal of cell biology.
[125] F. Baas,et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation , 2011, Neurobiology of Disease.
[126] M. Shoji,et al. Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene , 2006, Journal of neuroscience research.
[127] S. Nagata,et al. Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli , 1999, Oncogene.
[128] Bor Luen Tang,et al. Leptin as a neuroprotective agent. , 2008, Biochemical and biophysical research communications.
[129] Pinar Mesci,et al. Author manuscript, published in "Journal of Neural Transmission 2010;117(8):981-1000" DOI: 10.1007/s00702-010-0429-0 A G Barbeito et al. Motor neuron-immune interactions Motor neuron- immune interactions: the vicious circle of ALS , 2010 .
[130] T. Iwaki,et al. Impaired Cytoplasmic–Nuclear Transport of Hypoxia‐Inducible Factor‐1α in Amyotrophic Lateral Sclerosis , 2013, Brain pathology.
[131] S. Aquilonius,et al. Cholinergic, opioid and glycine receptor binding sites localized in human spinal cord by in vitro autoradiography Changes in amyotrophic lateral sclerosis , 1985, Acta neurologica Scandinavica.
[132] Adiponectin is Protective against Oxidative Stress Induced Cytotoxicity in Amyloid-Beta Neurotoxicity , 2012, PloS one.
[133] J. Turnbull,et al. Sonic Hedgehog is Cytoprotective against Oxidative Challenge in a Cellular Model of Amyotrophic Lateral Sclerosis , 2011, Journal of Molecular Neuroscience.
[134] G. Sobue,et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis , 2005, Annals of neurology.
[135] E. Stefani,et al. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[136] T. Holmøy,et al. T cells in amyotrophic lateral sclerosis , 2008, European journal of neurology.
[137] D. Price,et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[138] K. Jin,et al. Vascular Endothelial Growth Factor Overexpression Delays Neurodegeneration and Prolongs Survival in Amyotrophic Lateral Sclerosis Mice , 2007, The Journal of Neuroscience.
[139] E. Aronica,et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue , 2011, Neuroscience.
[140] T. Kanda,et al. FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons , 1999, International Journal of Developmental Neuroscience.
[141] John W Griffin,et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). , 2004, American journal of human genetics.
[142] T. Hortobágyi,et al. THE NEURONAL CELL CYCLE AS A MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE , 2008 .
[143] P. Mccombe,et al. The Role of Immune and Inflammatory Mechanisms in ALS , 2011, Current molecular medicine.
[144] E. Aronica,et al. Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-D-aspartic acid receptor , 2001, Acta Neuropathologica.
[145] Hitoshi Takahashi,et al. An Inducer of VGF Protects Cells against ER Stress-Induced Cell Death and Prolongs Survival in the Mutant SOD1 Animal Models of Familial ALS , 2010, PloS one.
[146] J. Julien,et al. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? , 2000, Journal of the Neurological Sciences.
[147] B. Brooks. A Summary of the Current Position of TRH in ALS Therapy a , 1989, Annals of the New York Academy of Sciences.
[148] D. Green,et al. Caspase-3 Is the Primary Activator of Apoptotic DNA Fragmentation via DNA Fragmentation Factor-45/Inhibitor of Caspase-activated DNase Inactivation* , 1999, The Journal of Biological Chemistry.
[149] E. Goodall,et al. Genetics of Familial Amyotrophic Lateral Sclerosis , 2012 .
[150] A. Chiò,et al. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? , 2010, CNS & neurological disorders drug targets.
[151] J. Kira,et al. Increased IL-13-producing T cells in ALS: Positive correlations with disease severity and progression rate , 2007, Journal of Neuroimmunology.
[152] P. V. van Rijen,et al. Expression and Cell Distribution of Group I and Group II Metabotropic Glutamate Receptor Subtypes in Taylor‐type Focal Cortical Dysplasia , 2003, Epilepsia.
[153] Christoph Schmitz,et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS , 2005, Nature Neuroscience.
[154] H. Zoghbi,et al. Neurobiology of disease , 2000, Current Opinion in Neurobiology.
[155] R. Ophoff,et al. A CASE OF ALS-FTD IN A LARGE FALS PEDIGREE WITH A K17I ANG MUTATION , 2009, Neurology.
[156] J. Loeffler,et al. Alteration of the Bcl-x/Bax Ratio in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis: Evidence for the Implication of the p53 Signaling Pathway , 2000, Neurobiology of Disease.
[157] A. Pizzuti,et al. Mitochondrial disfunction as a cause of ALS. , 2011, Archives italiennes de biologie.
[158] P. V. van Rijen,et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias , 2010, Epilepsia.
[159] J. Rothstein,et al. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis , 2009, Annals of neurology.
[160] Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2009, Acta neurologica Scandinavica.
[161] P. Shaw,et al. Molecular and cellular pathways of neurodegeneration in motor neurone disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[162] John Q. Trojanowski,et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS , 2010, Nature.
[163] Ewout J. N. Groen,et al. Meta-analysis of gene expression profiling in amyotrophic lateral sclerosis: A comparison between transgenic mouse models and human patients , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[164] B. Jeon,et al. Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity , 2009, Brain Research Reviews.
[165] H. Stępień,et al. Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis , 1986, Journal of Neurology.
[166] G. Rosoklija,et al. Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis , 2001, The Journal of Neuroscience.
[167] M. Cozzolino,et al. Mitochondrial dysfunction in ALS , 2012, Progress in Neurobiology.
[168] D. Cibrian,et al. Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model , 2010, Neurotoxicity Research.
[169] S. B. Caine,et al. Alterations in receptors for thyrotropin‐releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis , 1988, Neurology.
[170] S. Appel,et al. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS , 2012, Experimental Neurology.
[171] P. Poindron,et al. Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. , 2006, Life sciences.
[172] J. Thompson,et al. Astrocyte activation by fibroblast growth factor‐1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis , 2005, Journal of neurochemistry.
[173] A Hofman,et al. Genetic epidemiology of amyotrophic lateral sclerosis , 2003, Clinical genetics.
[174] L. Martin. p53 Is Abnormally Elevated and Active in the CNS of Patients with Amyotrophic Lateral Sclerosis , 2000, Neurobiology of Disease.